Skip to main content
Article thumbnail
Location of Repository

Efficacy of Clopidrogel on Reperfusion and High-Sensitivity C-Reactive Protein in Patients with Acute Myocardial Infarction

By Mehmet Akbulut, Makbule Kutlu, Yılmaz Ozbay, Veli Polat, Mehmet Nail Bilen, Adil Baydas and Yakup Altas


We investigated the effects of clopidogrel on reperfusion and inflammatory process in STEMI. A total of 175 STEMI patients with similar clinical characteristics were included to this study. One was the standard pharmacological reperfusion therapy group (group 1, n : 90), who received 300 mg aspirin, 70 U/kg bolus, and 12 U/kg/hr continuous infusion of unfractioned heparin and accelerated t-PA. Clopidogrel 450 mg loading and 75 mg/d thereafter was added to standard reperfusion therapy in the other group (group 2, n : 85). The ST-segment resolution, CK-MB, and high-sensitive CRP (hs-CRP) parameters were measured. Complete ST resolution was observed in 32 patients (36.8%) in group 1 and 53 patients (63.8%) in group 2 (P < .001). Also in the first 24 hours, the CK-MB levels of patients in group 1 were significantly higher than those of group 2 (P = .001). The hs-CRP values were greater in group 1 than group 2 at 48th hour (gruop 1: 9.4 ± 0.1 mg/L, group 2: 3.7 ± 1.4 mg/L; P = .000). We concluded that adding clopidogrel to standard treatment in STEMI patients provided early reperfusion and suppression of inflammatory response

Topics: Clinical Study
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1999). A n t m a n ,R .P .G i u g l i a n o ,C .M .G i b s o n ,e ta l . , “Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction
  2. (1997). Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor,”
  3. (2005). Angiographicandclinicaloutcomesinpatientsreceivinglowmolecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in
  4. (1998). CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells,”
  5. (1999). Clopidogrel as adjunctive antiplatelet therapy during coronary stenting,”
  6. (2002). Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and
  7. (2005). COMMIT(ClOpidogrelandMetoprololinMyocardialInfarction Trial) collaborative group, “Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction:
  8. (2001). Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein,”
  9. (2006). Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice,”
  10. (2005). Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics:
  11. (2004). Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention,”
  12. (2004). Effect of clopidogrel pretreatment on periprocedural rise in Creactive protein after percutaneous coronary intervention,”
  13. (1988). F r i n k ,P .A .R o o n e yJ r . ,J .O .T r o w b r i d g e ,a n dJ .P . Rose, “Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction,”
  14. (2002). Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin,” Thrombosis and Haemostasis,
  15. (1986). Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death,”
  16. (2005). M.S.Sabatine,C.P.Cannon,C.M.Gibson,etal.,“Additionof clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation,”
  17. (2008). Percutaneous coronary and valvular intervention,” in Braunwald’s Heart Disease:
  18. (2002). Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?”
  19. (2003). Scientific and therapeutic advances in antiplatelet therapy,”
  20. (2008). ST-elevation myocardial infarction: management,” in Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine,
  21. (2000). Stsegment resolution and infarct-related artery patency and flow after thrombolytic therapy,”
  22. (1997). Ticlopidine and aspirin interactions,”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.